Description:
Presents chapters written by leading clinical researchers in the field
of lung cancer, where high resolution 3-D imaging technology appears to
hold the greatest near-term promise, as well as contributions from
recognized experts in CAD, medical information technology systems,
regulatory procedure, x-ray standards development, and clinical trial
design. These expert contributors discuss the current state of the art
and provide a road map for directing further research in lung cancer as
well as other organ systems.
Table of Contents:
Preface (Thomas M. Baer and James L. Mulshine).
Chapter 1: Incorporating Imaging into Drug Development: An Industry Perspective (Philip S. Murphy and Debasish Roychowdhury).
Chapter 2: Developing Imaging Tools for Drug Development: Critical
Technology, Clinical Data and Regulatory (Rafal Dziadziuszko, Fred R.
Hirsch and Paul A. Bunn, Jr).
Chapter 3: Quantitative Imaging in CT Lung Cancer Drug Development and Evaluation (Ricardo S. Avila).
Chapter 4: Volumetric CT Imaging for Response Assessment in Lung
Cancer: A Platform for Translational Research (Binsheng Zhao and
Lawrence H. Scwhartz).
Chapter 5: Emerging Radiological Software Standards and
Development Technologies: Impact on Clinical Translation and Trials
(John Pearson, Lawrence Tarbox, Gianluca Paladini, John G. Wolodzko,
Paula M. Jacobs, and Zhenghong Lee).
Chapter 6: Statistical Considerations Underlying Therapeutic
Response Criteria for Lung Cancer: A Review in the Context of Emergence
of Multi-Slice CT Scanner and Computer Assisted Diagnostic Algorithm
for Volumetric Assessment (Madhu Mazumdar and Xi Kathy Zhou).
Chapter 7: Programs Supporting Quantitative Imaging in
Biomedicine at the National Institute for Standards and Technology
(Thomas M. Baer and Charles W. Clark).
Appendix A: Evolving Imaging Resources: Public Access Databases (Laurence Clarke).
Appendix B: Biomedical Imaging Archive Network (Thomas M. Baer and James L. Mulshine).
Appendix C: Developing CT Image-Processing Tools to Accelerate
Progress in Lung Cancer Drug Development (James L. Mulshine, Ricardo S.
Avila, Fred R. Hirsch, and David Yankelevitz).
| 
